Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?

Volume XX No. 8 - June 17, 2013

New MoPath Lab Coalition Takes its Case to Congress

Molecular Diagnostics / By

CEO SUMMARY: Prices recently established for molecular diagnostic tests are so low that they put patient access in jeopardy, declared a new lab industry coalition in a statement delivered to members of Congress. Called the Coalition to Strengthen the Future of Molecular Diagnostics, the organization also told members of Congress that—not only are the prices …

New MoPath Lab Coalition Takes its Case to Congress Read More »

To access this post, you must purchase The Dark Report.

Why a Divided Lab Industry May Soon Fall

Commentary and Opinion by R. Lewis Dark / By

OVER THE PAST TWO DECADES, it has often been remarked on these pages and by many others that the divided nature of the laboratory medicine profession will prove to be its ultimate Achilles heel. These divisions center around different scientific disciplines within pathology and lab medicine as well as the competing economic interests of the …

Why a Divided Lab Industry May Soon Fall Read More »

To access this post, you must purchase The Dark Report.

Big Lab Industry Stories Reveal Trouble Ahead

Laboratory Billing / By

CEO SUMMARY: One after another, a series of breaking news stories points to more rough waters ahead for the entire clinical lab industry. Of greatest interest is the ongoing questions about when clinical labs and pathology groups will get paid for the molecular test claims they have submitted to government and private payers since January …

Big Lab Industry Stories Reveal Trouble Ahead Read More »

To access this post, you must purchase The Dark Report.

Labs Have New Hurdles as Some Payments Start

Laboratory Billing / By

CEO SUMMARY: Some payments are beginning to flow for claims submitted under the new molecular test CPT codes. But there is a new issue. Medicare contractors, Medicaid programs, and private health insurers are deeming certain molecular tests to be medically unnecessary. These payers are requesting that labs submit more documentation before they will pay for …

Labs Have New Hurdles as Some Payments Start Read More »

To access this post, you must purchase The Dark Report.

Labs Face Consequences from MolDx Test ‘Mess’

Laboratory Billing / By

CEO SUMMARY: Non-payment of molecular test claims for the first five months of 2013 is not the only financial disruption for labs that perform these tests. Reports are coming in about how Medicare contractors, Medicaid programs, and private payers are declining to pay claims based on rulings that the molecular tests fail to meet medical …

Labs Face Consequences from MolDx Test ‘Mess’ Read More »

To access this post, you must purchase The Dark Report.

TriCore Lab Adds Value with Consults, Better TAT

Laboratory Management / By

CEO SUMMARY: Motivated by the goal of delivering more value to clinicians and client hospitals, the lab team at TriCore Reference Laboratories in Albuquerque, New Mexico, is proactively introducing new services. One such initiative is to travel to hospitals to participate in rounds and consult with physicians regularly. Another initiative improved the accuracy of C. …

TriCore Lab Adds Value with Consults, Better TAT Read More »

To access this post, you must purchase The Dark Report.

OIG Tells CMS It Could Save $910 Million on Lab Test Costs

Laboratory Management / By

IT IS ONE MORE POWERFUL SIGN of the changing times. Last week, the Office of the Inspector (OIG) publicly released a study it had done of the prices paid for lab testing and how the Medicare program could use this information to reduce the cost of Part B clinical laboratory testing. It was The Wall …

OIG Tells CMS It Could Save $910 Million on Lab Test Costs Read More »

To access this post, you must purchase The Dark Report.

June 17, 2013 “Intelligence: Late Breaking Lab News”

Late Breaking Lab News / By

Big news last week was the unanimous decision by the Supreme Court that natural genes cannot be patented. The case was brought against Myriad Genetics, Inc., by the American Civil Liberties Union, the Association for Molecular Pathology, and several other plaintiffs. The decision invalidated some of the patents held by Myriad for the BRCA 1 …

June 17, 2013 “Intelligence: Late Breaking Lab News” Read More »

To access this post, you must purchase The Dark Report.

Facebook-f Twitter Linkedin-in

The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: info@darkreport.com

© 2024 The Dark Report. All rights reserved.

;